Measures of Effect: An Introduction Epidemiology Supercourse Astana, July 2012 Philip la Fleur, RPh MSc(Epidem) Deputy Director, Center for Life Sciences.

Slides:



Advertisements
Similar presentations
Measures of effect: relative risks, odds ratios, risk difference and number needed to treat Giovanni Tripepi, Kitty J. Jager 1, Friedo W. Dekker 1,2, Christoph.
Advertisements

Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.
Data Analysis Basics for Analytic Epidemiology Session 3, Part 3.
Principles of case control studies Part I Nature of the design of case control studies Odds ratio as the measurement of association Piyanit Tharmaphornpilas.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
Step 3: Critically Appraising the Evidence: Statistics for Harm and Etiology.
Extension Article by Dr Tim Kenny
Understanding real research 3. Assessment of risk.
Confounding: An Introduction Epidemiology Supercourse Astana, July 2012 Philip la Fleur, RPh MSc(Epidem) Deputy Director, Center for Life Sciences
Introduction to Critical Appraisal : Quantitative Research
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Measures of Disease Association Measuring occurrence of new outcome events can be an aim by itself, but usually we want to look at the relationship between.
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
Mathew J. Reeves BVSc, PhD Associate Professor, Epidemiology
TREATMENT 1 Evaluation of interventions How best assess treatments /other interventions? RCT (randomised controlled trial)
BS Evidence Based Medicine And Atrial Fibrillation.
Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)
Are exposures associated with disease?
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Population Impact Measures (PIM)
Epidemiology 101: basic concepts
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 14 Screening and Prevention of Illnesses and Injuries: Research Methods.
Evidence Based Medicine and Medical Decision Making Iztok Hozo, Professor of Mathematics Indiana University Northwest European School of Oncology How to.
DEB BYNUM, MD AUGUST 2010 Evidence Based Medicine: Review of the basics.
Estimation of Various Population Parameters Point Estimation and Confidence Intervals Dr. M. H. Rahbar Professor of Biostatistics Department of Epidemiology.
Measures of Association
Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.
Evidence Based Practice in Psychology – Lecture 3 May 31, 2007.
Data Analysis & Interpretation Intermediate Injury Prevention August 23-26, 2011 Billings, MT.
How to Analyze Therapy in the Medical Literature (part 2)
CAT 3 Harm, Causation Maribeth Chitkara, MD Rachel Boykan, MD.
Understanding real research 4. Randomised controlled trials.
Measures of Association Professor Mobeen Iqbal Shifa College of Medicine.
Appraising Evidence into our Practice. Objectives Deciding the research result into practice in specific context Interpreting/calculating Number Needed.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2014)
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
O RGANIZING & DISPLAYING DATA Dr. Omar Al Jadaan Assistant Professor – Computer Science & Mathematics.
Statistics for clinicians Biostatistics course by Kevin E. Kip, Ph.D., FAHA Professor and Executive Director, Research Center University of South Florida,
November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Measures of Association and Impact Michael O’Reilly, MD, MPH FETP Thailand Introductory Course.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 6: “Number Needed to Treat” to Prevent One Case.
Measuring associations between exposures and outcomes
Evidence-Based Medicine – Definitions and Applications 1 Component 2 / Unit 5 Health IT Workforce Curriculum Version 1.0 /Fall 2010.
Learning Objectives Identify the model to create a well-built Clinical Question Differentiate between the various Evidence- Based Care Types of Questions.
Polypill x Aspirin Project Groups 3 and 4
Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.
Compliance Original Study Design Randomised Surgical care Medical care.
Case Control Studies Dr Amna Rehana Siddiqui Department of Family and Community Medicine October 17, 2010.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
From EBM to SDM: Michel Labrecque MD PhD Michel Cauchon MD Department of Family and Emergency Medicine Université Laval Teaching how to apply evidence.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Risk Different ways of assessing it. Objectives Be able to define and calculate: Absolute risk (reduction) Relative risk (reduction) Number needed to.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2015)
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Number Needed to Treat Alex Djuricich, MD Indiana University School of Medicine Department of Medicine Ambulatory Rotation
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
HelpDesk Answers Synthesizing the Evidence
CRITICAL APARAISAL OF A PAPER ON THERAPY
Systolic Blood Pressure Intervention Trial (SPRINT)
remember to round it to whole numbers
1 Information Mastery Skills Calculating RR, RRR, ARR and NNTs A. Bornstein, MD, FACC Assistant Professor of Medicine Weil Cornell Medical College New.
Measurements of Risk & Association …
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
Basic statistics.
Presentation transcript:

Measures of Effect: An Introduction Epidemiology Supercourse Astana, July 2012 Philip la Fleur, RPh MSc(Epidem) Deputy Director, Center for Life Sciences

Come to Ottawa, Canada and get “Out and About”

Canadian Agency for Drugs and Technologies in Health ( Emerg Med J 2003;20:

Objectives Understand how to calculate and interpret and articulate measures of effect and morbidity 1.2x2 Table Risk Odds Relative Risk Odds Ratio 2.Relative Risk Reduction and Absolute Risk Reduction 3.Number needed to Treat and Number needed to Harm

Summary Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

1. 2x2 Table Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

Risk Probability that an event will occur (Last 2001) E.g. that a person will die within one year Risk in Exposed = a/(a+b) Risk in unexposed, “Baseline risk” = c/(c+d) Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

Odds The ratio of the probability of occurrence of an event to that of non-occurrence E.g. odds of smokers developing a chronic cough Odds in Exposed = a/b Odds in unexposed, “Baseline odds” = c/d Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

Risk Versus Odds RiskOdds Conversion: Odds = Risk/(1-Risk) Risk = Odds / (1 + Odds) ⌂⌂⌂⌂/⌂ ⌂⌂/⌂ ⌂/⌂ ⌂/⌂⌂⌂⌂ ⌂/⌂⌂⌂⌂⌂⌂⌂⌂⌂

Would you swim here?

Develop a Question: PICO P opulation: children under 5 years of age I ntervention (exposure): Swimming in the Ishim River C omparator (control): Not swimming in the Ishim river O utcome: Otitis Media Question: What is the risk that a child under 5 will develop an ear infection after swimming in the Ishim river?

Odds Ratio Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

Odds Ratio Odds of getting infection for swimmers: 40/60 = 0.67 Ear Infection Total Swimming in Ishim YesNo Yes No Total Odds of getting infection for non-swimmers: 5/95 = 0.052

Relative Risk Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

Relative Risk Risk of getting infection for swimmers: 40/100 = 0.4 Ear Infection Total Swimming in Ishim YesNo Yes No Total Risk of getting infection for non-swimmers: 5/100 = 0.05

OR versus RR Key Messages Odds and Odds Ratios are difficult to conceptualize but statisticians prefer them in some situations because of their mathematical properties Odds Ratios always exaggerate the relative risk, but when baseline risk is low (e.g. <10%), the OR approximates the relative risk Relative Risk is a more intuitive measure and is becoming more common in medical literature

Objectives Understand how to calculate and interpret and articulate measures of effect and morbidity 1.2x2 Table Risk Odds Relative Risk Odds Ratio 2.Relative Risk Reduction and Absolute Risk Reduction 3.Number needed to Treat and Number needed to Harm

2. Relative Risk Reduction and Absolute Risk Reduction Objectives Learn how to interpret risk of events in the control (baseline group) and intervention groups (treatment group) from published studies. Understand the concepts of relative risk reduction and absolute risk reduction and how they usually differ from one population to another.

Trial 1: High Risk Patients – New drug for acute myocardial infarction to reduce mortality – First studied in a high risk population: 40% mortality at 30 days among untreated e.g., elderly, heart failure, anterior wall infarction Ref:

Trial 1: High Risk Patients – New drug for acute myocardial infarction to reduce mortality – First studied in a high risk population: 40% mortality at 30 days among untreated e.g., elderly, heart failure, anterior wall infarction 30% mortality among treated – How would you describe the effect of the new drug? Ref:

Trial 1: High Risk Patients Ref:

Trial 2: Low Risk Patients – New drug for acute myocardial infarction to reduce mortality – Later studied in a lower risk population: 10% mortality at 30 days among untreated e.g., younger, uncomplicated inferior wall infarction Ref:

Trial 2: Low Risk Patients – New drug for acute myocardial infarction to reduce mortality – Later studied in a lower risk population: 10% mortality at 30 days among untreated e.g., younger, uncomplicated inferior wall infarction 7.5% mortality among treated – How would you describe the effect of the new drug? Ref:

Trial 2: Low Risk Patients Ref:

Summary Points for Relative Risk Reduction and Risk Difference Relative risk reduction is often more impressive than absolute risk reduction. The lower the risk in the control group, the larger the difference between relative risk reduction and absolute risk reduction.

Objectives Understand how to calculate and interpret and articulate measures of effect and morbidity 1.2x2 Table Risk Odds Relative Risk Odds Ratio 2.Relative Risk Reduction and Absolute Risk Reduction 3.Number needed to Treat and Number needed to Harm

3. Number Needed to Treat Number Needed to Harm Objectives Learn how to calculate Number Needed to Treat (NNT) from an estimate of risk difference. Increase awareness of the range of NNTs associated with common interventions.

Definitions Number Needed to Treat (NNT): – Number of persons who would have to receive an intervention for 1 to benefit. Number Needed to Harm(NNH): – Number of persons who would have to receive an intervention for 1 to be experience a adverse event.

Calculating NNT If a disease has a mortality of 100% without treatment and therapy reduces that mortality to 50%, how many people would you need to treat to prevent 1 death?

Estimate NNT CER%EER%ARR%NNT How many 60-year-old patients with mild hypertension would you have to treat with diuretics for 5 years to prevent 1 stroke? How many people with myocardial infarction would you have to treat with ß- blockers for 2 years to prevent 1 death? How many people with acute myocardial infarction would you have to treat with streptokinase to prevent 1 person from dying in the next 5 weeks? Ref:

Estimate NNT CER%EER%ARR%NNT How many 60-year-old patients with hypertension would you have to treat with diuretics for 5 years to prevent 1 death? How many people with myocardial infarction would you have to treat with ß-blockers for 2 years to prevent 1 death? How many people with acute myocardial infarction would you have to treat with streptokinase to prevent 1 person from dying in the next 5 weeks? Ref:

Estimate NNT CER%EER%ARR%NNT How many 60-year-old patients with hypertension would you have to treat with diuretics for 5 years to prevent 1 death? How many people with myocardial infarction would you have to treat with ß- blockers for 2 years to prevent 1 death? How many people with acute myocardial infarction would you have to treat with streptokinase to prevent 1 person from dying in the next 5 weeks? Ref:

Calculation NNT= 100/ARR (where ARR is %) or NNT= 1/ARR (where ARR is proportion) NNH= 100/ARI (where ARI is %) Or NNH = 1/ARI (where ARI is proportion)

NNTs from Controlled Trials Control Event % Treatment Event % Absolute Risk Reductio n% NNT Population: hypertensive 60-year-olds Therapy: oral diuretics Outcome: stroke over 5 years Population: myocardial infarction Therapy: ß-blockers Outcome: death over 2 years Population: acute myocardial infarction Therapy: streptokinase (thrombolytic) Outcome: death over 5 weeks Ref:

Population: hypertensive 60-year-olds Outcome: stroke over 5 years Depiction of Results in Control Group Ref:

Population: hypertensive 60-year-olds Outcome: stroke over 5 years Depiction of Results in Treatment Group Ref:

Bottom Line It is easy to mis-estimate baseline risk and effects of therapy NNT is easily calculated from the absolute risk reduction (ARR) Awareness of threshold NNT can help anticipate the risk reduction to look for in a therapy.

Summary Outcome Total ExposureYesNo Yesaba + b Nocdc + d Totala + c b + dN

References/Slide Sources 1.Last JM. A Dictionary of Epidemiology, 4th ed. Oxford University Press, Guyatt G et al. Users’ Guides to the Medical Literature, 2nd ed. McGraw Hill, Guyatt G. Tips for Teachers of Evidence Based Medicine. Lecture on Odds and Risk. 4.Grimes and Schulz. Making Sense of Odds and Odds Ratios. Obs & Gyn 2008(111): Some Slides for Risk Reduction and NNT are from: Alexandra Barratt, Peter C. Wyer, Rose Hatala, Thomas McGinn, Antonio L. Dans, Sheri Keitz, Virginia Moyer, Gordon Guyatt, Robert Hayward, for the EBM Teaching Tips Working Group ( 6.Smiley Diagrams from: Dr. Chris Cates EBM Website: